Physician profile
Guiling Yang
NPI 1891033387
$1,337.09
in general payments reported to CMS, 2019-2025
11 companies · $997 in 2025
The $997 reported for 2025 was more than what 84% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $125 · 2024: $215 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,337.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $201.76 | 2025 | Twiist |
| Cequr Corporation | $185.96 | 2025 | Cequr Simplicity |
| Beta Bionics, INC. | $172.08 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Novo Nordisk INC | $126.35 | 2024-2025 | Wegovy |
| Horizon Therapeutics Plc | $125.00 | 2023 | Tepezza |
| Tandem Diabetes Care, INC. | $113.28 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascensia Diabetes Care US INC. | $112.99 | 2025 | |
| Lilly USA, LLC | $109.44 | 2025 | |
| Sanofi-Aventis U.S. LLC | $91.36 | 2025 | |
| Alexion Pharmaceuticals, INC. | $57.79 | 2024 | |
| Amgen INC. | $41.08 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guiling Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.